The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis
Christopher E Starr, Kelly K Nichols, Jacob R Lang, Todd C Brady · 2023
Read The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis by Christopher E Starr, Kelly K Nichols, Jacob R Lang, Todd C Brady (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725700.txt.
Description
Christopher Starr and co-authors report a phase 3 trial of an eye drop, reproxalap, for seasonal allergy of the eye. Their 2023 trial enrolled adults with a history of moderate to severe allergic conjunctivitis and ragweed allergy, whose itching and redness flared inside an allergen chamber. Ninety-five patients were assigned to start on the drug or a plain vehicle drop, then swapped after a two-week washout.
Itching from about two to three and a half hours after chamber entry was the main measure, with redness as the key second measure. Eighty-nine patients finished all visits. The drug works by trapping reactive aldehyde species, chemicals that drive allergic swelling, and the trial tests it under real-world style exposure.
Catalog record
| CREATOR | Christopher E Starr, Kelly K Nichols, Jacob R Lang, Todd C Brady |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |